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Abstract
Introduction: Th17 cells have been implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this
study was to systematically analyse the phenotype, cytokine profile and frequency of interleukin-17 (IL-17)
producing CD4-positive T cells in mononuclear cells isolated from peripheral blood, synovial fluid and synovial
tissue of RA patients with established disease, and to correlate cell frequencies with disease activity.
Methods: Flow cytometry was used to analyse the phenotype and cytokine production of mononuclear cells
isolated from peripheral blood (PBMC) (n = 44), synovial fluid (SFMC) (n = 14) and synovium (SVMC) (n = 10) of RA
patients and PBMC of healthy controls (n = 13).
Results: The frequency of IL-17-producing CD4 T cells was elevated in RA SFMC compared with RA PBMC (P =
0.04). However, the frequency of this population in RA SVMC was comparable to that in paired RA PBMC. The
percentage of IL-17-producing CD4 T cells coexpressing tumor necrosis factor alpha (TNFa) was significantly
increased in SFMC (P = 0.0068). The frequency of IFNg-producing CD4 T cells was also significantly higher in SFMC
than paired PBMC (P = 0.042). The majority of IL-17-producing CD4 T cells coexpressed IFNg. IL-17-producing CD4 T
cells in RA PBMC and SFMC exhibited very little IL-22 or IL-23R coexpression.
Conclusions: These findings demonstrate a modest enrichment of IL-17-producing CD4 T cells in RA SFMC
compared to PBMC. Th17 cells in SFMC produce more TNFa than their PBMC counterparts, but are not a
significant source of IL-22 and do not express IL-23R. However, the percentage of CD4 T cells which produce IL-17
in the rheumatoid joint is low, suggesting that other cells may be alternative sources of IL-17 within the joints of
RA patients.
Introduction
Rheumatoid arthritis (RA) is a systemic chronic inflam-
matory disorder associated with persistent and destruc-
tive synovitis leading to cartilage and bone erosion. The
underlying cause of RA is unknown; however, the patho-
g e n e s i so fR Ai st h o u g h tt ob ethe result of complex cell
to cell interactions between amongst others, T cells,
macrophages and fibroblasts. In established disease, the
preponderance of IFNg-expressing and paucity of IL-4-
expressing T cells, in situ and ex vivo, had until recently
led to the description of RA as an immune mediated
inflammatory disease associated with a predominantly
T helper type-1 (Th1)-like cytokine profile [1-3].
More recently, effector T cells (Th17 cells), that produce
interleukin-17A (IL-17) [4,5] and that are functionally dis-
tinct from Th1 and Th2 helper T cells, have been identi-
fied in mice and subsequently in humans [6]. Th17 cells
have an important role in the clearance of extracellular
bacteria and fungi, but also appear to play a pathogenic
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any medium, provided the original work is properly cited.role in several inflammatory and autoimmune diseases. In
experimental animal models, IL-17-producing T cells are
involved in the pathogenesis of experimental autoimmune
encephalomyelitis (EAE), collagen-induced arthritis (CIA),
colitis and psoriasis [7-9].
In mice, the development of Th17 cells is driven by
the transcription factor retinoic acid-related orphan
receptor gt( R O R gt). Differentiation from naïve T cells
requires TGFb, IL-1, and IL-6 [10,11]. In humans, the
origin of Th17 cells and the factors that regulate their
development remain controversial, but like murine Th17
cells, IL-1 and IL-6 are essential and it is likely that
TGF-b also plays a role. Both murine and human Th17
cells require IL-23 for their expansion and survival.
Th17 differentiation is not only regulated by cytokines
but also by environmental and dietary factors, such as
aryl hydrocarbons [12,13] and vitamin D3 [14,15]. In
addition to IL-17, Th17 cells have been shown to pro-
duce IL-21, IL-22, TNFa and IFNg [16].
In RA, IL-17 has been detected in synovial fluid (SF)
and synovium [17-21]. Its expression is associated with
inflammation and joint destruction, as well as with pro-
duction of IL-1b and TNFa. In addition to stimulating
the production of these proinflammatory cytokines, IL-
17 acts synergistically by amplifying their effects [22,23].
We have previously identified IL-17-producing T cells
within SF and synovial tissue, and demonstrated that
RA synovial fibroblasts treated with IL-17 and TNFa
promote the survival and functional lifespan of neutro-
phils, contributing to the increased number of neutro-
phils observed in the rheumatoid synovial
microenvironment [23]. Based upon the combined evi-
d e n c ef o rar o l eo fI L - 1 7i ni n f l a m m a t i o n ,t a r g e t i n go f
IL-17 is now being tested as a new therapeutic strategy
for the treatment of RA [24].
However, relatively little is known about the pheno-
type, cytokine profile and frequency of Th17 cells in the
synovial environment and how they relate to RA disease
activity. Two reports have shown that the frequency of
Th17 cells was increased in the blood of RA patients
compared with healthy donors [15,25], whilst Shahrara
et al. demonstrated that the percentage of Th17 cells
was higher in RA SF compared with normal and RA
peripheral blood [15,25,26]. In addition, IL-17-producing
T cells were shown to be enriched in the joints of chil-
dren with juvenile idiopathic arthritis [27]. In contrast,
Yamada et al. reported fewer Th17 cells in the joints of
RA patients compared to peripheral blood [28]. In light
of these conflicting data, we investigated the phenotype
and frequency of IL-17-producing T cells in the blood,
SF and synovial tissue of patients with RA, examining
the cytokine profile of this population and correlation
with disease activity.
Materials and methods
Patients
Paired blood and SF was obtained from 14 RA patients
(nine female) meeting the 1987 ACR criteria [29] with a
median age of 60.5 years (interquartile range (IQR) 52 to
69.5), and a median DAS28 of 5.55 (IQR 4.41 to 6.11).
Paired blood and synovium was obtained from 10 RA
patients (nine female) meeting the 1987 ACR criteria [29]
with a median age of 56 years (IQR 48 to 71), and a med-
ian DAS28 of 4.75 (IQR 4.08 to 5.95) undergoing joint
replacement surgery. The clinical details of patients who
donated blood and SF or synovium are given in Table 1.
Peripheral blood samples were obtained from an addi-
tional 20 RA patients (10 female) giving a total of 44 RA
blood samples analysed. Blood from 13 healthy control
(HC) donors (six female) with a median age of 56 years
(IQR 51.5 to 62) was obtained. Details of the 44 RA
patients for whom analysis of blood was conducted are
given in Table 2. Ethical approval for this study was given
by the local research ethics committee and all subjects
gave written informed consent.
Peripheral blood and synovial fluid cell preparation
Peripheral blood mononuclear cells (PBMC) and SF
mononuclear cells (SFMC) were isolated by density gra-
dient centrifugation on Ficoll-paque™-Plus (GE Health-
care, Amersham, UK), washed twice with RPMI-1640
m e d i u m( S i g m a - A l d r i c h ,S tL o u i s ,M O ,U S A ) ,c o u n t e d
using a Neubauer hemocytometer and resuspended at
1×1 0
6 cells/ml in fresh medium.
Synovial tissue dissociation
RA synovium was cut into small pieces and washed in
RPMI-1640 medium. The tissue suspension was trans-
ferred into a Stomacher® 400 Circulator Bag (Seward
Ltd, Worthing, UK), heat sealed, placed in a Stomacher®
400 circulator (Seward Ltd) and run at 230 rpm for five
minutes. The contents of the bag were removed and
passed through a BD Falcon 70 mm nylon cell strainer.
The filtered cell suspension was then layered onto ficoll
and synovial tissue mononuclear cells (SVMC) isolated
from the buffy coat following centrifugation as above.
Flow cytometric analysis
Monoclonal antibodies (mAb) and reagents used for flow
cytometric analysis were phycoerythrin (PE)-conjugated
anti-IL-17A mAb (eBioscience, San Diego, CA, USA), anti-
IL-4 mAb (BD Biosciences, Franklin Lakes, NJ, USA), anti-
CD4 mAb (Immunotools, Friesoythe, Germany); fluorescein
isocyanate (FITC)-conjugated anti-interferon-g mAb (Invi-
t r o g e n ,P a i s l e y ,U K ) ,a n t i - I L - 6m A b( e B i o s c i e n c e ) ,
anti-TNFa mAb (BD Biosciences), anti-IL-10
mAb (eBioscience), anti-CD4 mAb (Immunotools),
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23R mAb (R&D Systems, Abingdon, UK); allophycoerythrin
(APC)-conjugated anti-IL-22 mAb (R&D Systems), anti-
CD45RA mAb (Southern Biotech, Birmingham, AL, USA),
anti-CD8 mAb (Biolegend, San Diego, CA, USA); pacific
blue (PcB)-conjugated anti-CD4 mAb (eBioscience); PE-
Cy7-conjugated anti-CD3 mAb (eBioscience); PE-Cy647-
conjugated anti-CD14 mAb (Immunotools). Stained cells
were run on a Cyan flow cytometer (Dako), and the data
analysed using Summit v4.3 software (Dako).
Intracellular staining of cytokines
Mononuclear cells were stimulated with 100 ng/ml
of phorbol myristate acetate (PMA) (Sigma-Aldrich) and
Table 1 Characteristics of RA patients for whom analysis of IL-17-positive CD4 T cells in paired blood and synovial
fluid (top), and paired blood and synovium (bottom) was performed
Treatment % CD3+CD4+
IL17+
Subject RF ACPA Disease duration, years DMARD Anti-TNF Steroid ESR,
mm/hr
CRP,
mg/l
DAS28
(ESR)
PBMC SFMC
1 +ve +ve <1 MTX,
HCQ
N N 39 15 6.20 1.95 2.52
2 +ve +ve 2 MTX, HCQ N N 61 8 7.01 1.09 0.82
3 +ve +ve 1 N N N 21 7 4.18 2.36 2.17
4 +ve -ve 23 MTX N N 18 11 5.83 0.73 0.79
5 +ve -ve 45 MTX N N 60 11 5.27 0.63 0.53
6 +ve +ve 5 MTX, SSZ N N 69 93 5.48 2.34 2.84
7 +ve +ve 4 N Y Y 28 30 3.51 3.48 1.17
8 +ve +ve <1 MTX,
HCQ
N Y 63 72 6.14 1.59 1.44
9 +ve +ve 5 N Y Y 32 12 5.62 1.30 7.90
10 +ve +ve <1 MTX Y N 80 71 6.08 0.73 5.18
11 -ve +ve 1 N N N 10 15 5.76 0.86 3.48
12 +ve +ve 5 MTX Y Y 24 24 4.42 1.06 1.06
13 -ve -ve 6 HCQ N N 81 92 4.39 0.37 4.45
14 +ve +ve 1 MTX N Y 17 16 4.48 0.49 0.46
Treatment % CD3+CD4+
IL17+
Subject RF ACPA Disease duration, years DMARD Anti-TNF Steroid ESR,
mm/hr
CRP,
mg/l
DAS28
(ESR)
PBMC SVMC
1 +ve +ve 16 N Y N 20 20 3.83 0.77 0.55
2 +ve +ve 4 N Y Y 13 9 4.95 0.57 0.48
3 +ve +ve 5 N Y Y 13 3 4.50 1.63 0.78
4 -ve +ve 8 MTX Y N 12 0 3.57 1.49 1.08
5 +ve +ve 20 N N Y 89 24 6.03 2.63 0.91
6 +ve +ve 23 N N Y 45 57 5.86 0.08 0.24
7 +ve +ve 20 SSZ N N 31 11 4.33 0.73 0.81
8 +ve +ve 5 N Y Y 15 3 4.55 0.29 1.17
9 -ve -ve 15 N Y N 115 22 6.19 1.37 0.99
10 -ve +ve 1 LEF N N 10 15 5.76 1.65 0.48
-ve, negative; +ve, positive; ACPA, anti-CCP antibodies; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N, no; PB, peripheral blood; RF,
rheumatoid factor; SF, synovial fluid; SSZ, sulfasalazine; SVMC, synovium mononuclear cells; Y, yes.
Table 2 Summary of RA patients for whom analysis IL-17-
positive CD4 T cells in the blood was conducted
RA patients (n) 44
Age, years (median (IQR)) 56 (50 to 65.5)
Sex, female (n) 28
Disease duration, years (median (IQR)) 3.5 (1.0 to 5.5)
RF positive (n) 32
ACPA positive (n) 30
ESR, mm/hr (median (IQR)) 24 (10 to 40)
CRP, mg/ml (median (IQR)) 11 (<5 to 23)
DAS28 (ESR) (median (IQR)) 5.15 (4.01 to 6.17)
% IL17-positive CD4 T cells (median (IQR)) 1.08 (0.60 to 1.64)
% IL17-positive CD45RO CD4 T cells (median (IQR)) 1.10 (0.47 to 1.79)
IQR, interquartile range.
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together with 2 μg/ml of brefeldin A (Sigma-Aldrich).
This time-point was identified prior to this study, in a
time-course experiment, as the optimum for intracellu-
lar cytokine measurement of IL-17 and IFNg (the prime
discriminators between Th1/Th17 cells) (data not
shown). After surface staining, intracellular staining was
performed using a Caltag fixation and permeabilisation
kit (Invitrogen) according to manufacturer’s instructions.
Statistical analysis
Correlations were examined using Spearman rank test.
For comparisons of unpaired and paired samples, the
Mann-Whitney U test and Wilcoxon signed rank test
were used respectively, with two-tailed P-values. Med-
ians and interquartile ranges (IQR) are reported.
P-values less than 0.05 were considered significant.
Results
Frequencies of IL-17-producing CD4 T cells in PBMC,
SFMC and SVMC of patients with RA
Flow cytometry was used to measure the intracellular
expression of IL-17 following stimulation with PMA and
ionomycin in CD4 T cells from peripheral blood, SF
and mechanically dissociated synovial tissue of RA
patients and from the peripheral blood of healthy
donors. The frequencies of IL-17-producing CD4 T cells
in PBMC and SFMC of patients with RA were variable.
The median proportion of IL-17-producing CD4 T cells
in SFMC (n = 14) (1.81% (0.81 to 3.97)) was significantly
(P = 0.04) greater than in PBMC (n = 44) (1.08% (0.60
to 1.64)) from RA patients, and increased compared
with PBMC (n = 13) (0.84% (0.58 to 1.40)) from healthy
controls (Figure 1A, 1B). Examination of the frequency
of IL-17-producing CD4 T cells in paired samples from
RA patients also confirmed an enrichment of this popu-
lation in the SFMC (1.81% (0.81 to 3.97)) compared
with PBMC (1.08% (0.68 to 2.15)) (Figure 1C). Conver-
sely, we observed a lower median proportion of
IL-17-producing CD4 T cells in cells isolated from RA
synovium (SVMC) (0.80% (0.48 to 1.04)) compared with
PBMC (1.07% (0.43 to 1.64)) from those individuals
(Figure 1C). However, none of these differences reached
statistical significance.
As previous reports have identified the vast majority
of IL-17-positive cells to be found within the memory
(CD45RO) CD4 population, we examined the frequen-
cies of IL-17-producing CD4-positive CD45RO-positive
T cells from the peripheral blood and SF of RA patients
and compared these with the peripheral blood of healthy
donors (Figure 1D). The frequency of these cells
amongst SFMC (n = 14) (2.35% (0.95 to 4.91)) was sig-
nificantly higher (P = 0.008) compared to RA PBMC (n
= 44) (1.10% (0.47 to 1.79)). The frequency of IL-17-
producing CD4-positive CD45RO-positive T cells in
PBMC of RA patients was significantly lower (P =
0.009) than the PBMC of healthy controls (n =1 3 )
(1.91% (1.32 to 2.30)).
There were no significant correlations between the
DAS28 or DAS28 components (CRP and swollen and
tender joint counts) and the frequencies of IL-17-produ-
cing CD4 T cells in PBMC, SFMC, or SVMC in patients
with RA. As only 3 of the 14 RA patients for whom we
had obtained SF were anti-CCP antibody negative
(ACPA -ve), we were unable to draw conclusions
regarding the frequencies of IL-17-producing CD4 T
cells in SFMC of anti-CCP antibody positive (ACPA
+ve) versus ACPA -ve patients. However, there was no
difference in the frequency of IL-17-producing CD4 T
cells in the peripheral blood between ACPA +ve (1.00%
(0.36 to 1.72)) and ACPA -ve (0.97% (0.38 to 1.94)) RA
patients. Also, there were no correlations between the
frequencies of IL-17-producing CD4 T cells and the
D A S 2 8 ,w h e nA C P A+ v ea n dA C P A- v eR Ap a t i e n t s
were examined separately. Examination of the DAS28 in
patients segregated on the basis of a high frequency
(≥1.0%) versus low frequency (<1.0%) of SF IL-17-posi-
tive CD4 T cells found no significant difference between
these groups.
IFNg co-expression by IL-17-positive CD4 T cells in PBMC,
SFMC and SVMC of patients with RA
RA has previously been deemed a Th1 disease and IL-
17-producing CD4 T cells are capable of coexpressing
the archetypical Th1 cytokine, IFNg. We thus examined
the frequency of IFNg-positive CD4 T cells in relation
to IL-17-positive CD4 T cells within blood, SF and
SVMC of patients with RA. In both the peripheral blood
and SF of RA patients, the majority of CD4 T cells
expressed IFNg (Figure 2A, 2B) with the frequency of
IFNg-positive IL-17-negative T cells significantly higher
in the SFMC (77.75% (62.37 to 85.93)) compared to
PBMC (59.97% (31.07 to 78.27)) (P =0 . 0 4 2 ) .T h e r ew a s
no significant difference between the median frequency
of IFNg IL-17 double positive CD4 T cells amongst
SFMC (0.83% (0.46 to 2.12)) and PBMC (0.31% (0.14 to
0.82)) or in the median frequency of the IFNg-negative
IL-17-positive subset between the PBMC (0.37% (0.12 to
1.30)) and SFMC (0.25% (0.12 to 0.62)). There was an
inverse relationship between the frequencies of IFNg-
positive IL-17-negative cells and IFNg-negative IL-17-
positive CD4 T cells in SFMC (r = -0.66, P = 0.01).
The pattern of IFNg and IL-17 expression in PBMC
and SVMC CD4 T cells (Figure 2C), was similar to that
seen in PBMC and SFMC (Figure 2B). There were no
significant correlations between the frequencies of any
of the subsets and the DAS28. In a previous study, the
use of methotrexate (MTX) or prednisolone was
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C D 4Tc e l l si nP B M C[ 2 8 ] .I no u rs t u d yh o w e v e r ,w e
observed that the frequency of IL-17-positive CD4
T cells in PBMC (1.07% (0.59 to 1.77), n =2 2 )i n
patients taking MTX or prednisolone was marginally
lower compared to patients not receiving these drugs
(1.34% (0.53 to 1.64), n = 22). There was no difference
in disease activity between these two groups. Of the 14
patients in whom SFMC were analysed, nine were taking
MTX and these patients also had a lower frequency of
Figure 1 Frequency of IL-17-positive CD4 T cells in PBMC, SFMC, and synovium (SVMC) of RA patients versus PBMC of healthy donors.
Cells were stimulated with PMA and ionomycin in the presence of brefeldin A. A) Representative plots of IL-17 staining on PBMC of healthy
controls (HC), RA PBMC, and RA SFMC are shown against CD3. Cells were first gated on CD3 and CD4 expression. The percentages of IL-17
positive cells are indicated. B) The frequency of IL-17-positive CD4 T cells was compared between RA and healthy control samples. Data from
healthy control PBMC (n = 13), RA PBMC (n = 44) and SFMC samples (n = 14) are shown. C) Data from healthy control PBMC (n = 13), RA paired
PBMC and SFMC samples (n = 14) and paired RA PBMC and SVMC samples are shown (n = 10). D) The frequency of IL-17-positive CD4 CD45RO
T cells was compared between healthy donor PBMC (n = 13), RA PBMC (n = 44) and RA SFMC (n = 14). Bars representing the medians are
shown within the dot plots. P-values less than 0.05 were considered significant.
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Page 6 of 13IL-17-positive CD4 T cells in the SFMC (1.06% (0.66 to
2.68)) compared with the five patients not receiving
MTX (3.48% (1.67 to 6.18)). Only one patient from
whom synovial tissue was obtained was taking MTX,
and therefore this association was not examined. There
were also no differences between the frequencies of IL-
17-positive CD4 T cells in patients receiving or not
receiving biologic agents in PBMC, SFMC or SVMC.
Analysis of IL-22 and IL-23R expression on IL-17-positive
CD4 T cells in PBMC and SFMC of patients with RA
IL-22 is produced by Th17 cells [9,30,31] and has been
implicated in RA [32,33], whilst IL-23 is thought to be
critical for the expansion and survival of Th17 cells. We
examined the frequency of IL-22 and IL-23-receptor
(IL-23R) coexpression in IL-17-positive T cells within
the SF and peripheral blood of patients with RA. IL-22
and IL-17 double positive CD4 T cells (Figure 3A) were
hardly detectable in PBMC (0.07% (0.02 to 0.30)), or
SFMC (0.16% (0.04 to 0.35)) of RA patients and PBMC
(0.16% (0.07 to 0.21)) of healthy controls. The median
percentage of IL-17-positive CD4 T cells coexpressing
IL-22 did not significantly differ between SFMC (7.90%
(5.57 to 16.23)), RA PBMC (15.13% (3.36 to 26.76)) and
PBMC of healthy donors (14.29% (9.37 to 23.85)) (Fig-
ure 3B). Furthermore, the total frequency of IL-22-posi-
tive CD4 T cells was not significantly elevated in RA
PBMC (1.09% (0.24 to 4.19)) and SFMC (1.12% (0.40 to
2.03)) compared with PBMC of healthy controls (0.87%
(0.45 to 1.32)) (Figure 3C).
Despite the low frequency of IL-17-positive CD4 T
cells coexpressing IL-22, the frequency of IL-22-positive
CD4 T cells correlated strongly with the frequency of
IL-17-producing CD4 T cells in PBMC of RA patients (r
= 0.57, P < 0.0004); this correlation was not evident in
SFMC (r = 0.35, P = 0.22). The frequency of IL-22-posi-
tive CD4 T cells in RA SFMC showed an inverse corre-
lation with the DAS28 (r = -0.67, P = 0.008).
Interestingly, we detected very little expression of IL-
23R on IL-17-positive CD4 T cells (Figure 3D, 3E). There
was a non-significant trend towards a higher frequency
of total CD4 T cells expressing IL-23R in RA SFMC
(6.28% (3.63 to 9.07)) and RA PBMC (3.65% (2.07 to
5.31)) compared with the PBMC of healthy controls
(2.38% (1.68 to 4.74)) (Figure 3F). In contrast to the IL-
22-positive CD4 T cells, the frequency of IL-23R-positive
CD4 T cells did not correlate with IL-17-producing CD4
T cells in either PBMC or SFMC compartments, nor was
there any correlation with disease activity.
Coexpression of TNFa by IL-17-producing CD4 T cells in
PBMC and SFMC of patients with RA
Given that TNFa plays an important role in the patho-
genesis and persistence of RA, we examined whether
IL-17-producing CD4 T cells coexpressed TNFa (Figure
4A). As anticipated, the frequency of TNFa-producing
CD4 T cells in SFMC was significantly elevated (76.24%
(57.77 to 86.97)) compared with PBMC (47.66% (28.24
to 65.79)) in patients with RA (P = 0.032) (Figure 4B).
To determine whether IL-17-producing CD4 T cells
were found within this population we determined the
percentage of IL-17-positive CD4 T cells that coex-
pressed TNFa (Figure 4C). Despite almost all IL-17-
positive CD4 T cells expressing TNFa this subset made
up less than 1.0% of all CD4 T cells in the SFMC
(0.82% (0.51 to 1.56)) compared with 74.09% (57.18 to
85.44) CD4 T cells expressing TNFa but not IL-17 in
the SFMC (Figure 4D). However in RA SFMC, signifi-
cantly more IL-17-positive CD4 T cells coexpressed
TNFa (94.55% (88.06 to 97.77)) compared with only
72.22% (61.29 to 87.43) found in matched RA PBMC
(P = 0.0068) and 79.27% (61.80 to 89.87) in healthy con-
trol PBMC.
Production of IL-6 by IL-17-producing CD4 T cells
was also examined however most IL-17-producing CD4
T cells failed to produce IL-6 (data not shown).
Discussion
There is considerable evidence, from both animal and
human studies, that IL-17 plays a role in inflammatory
arthritis [17-21,34]. Mechanistically, IL-17 promotes
osteoclastogenesis, partly through upregulation of
RANKL expression [35], and also synergises with other
inflammatory cytokines, such as TNFa and IL-1, to
amplify their effects [22,23]. These observations have led
to the development of new therapeutic strategies aimed
at targeting IL-17 or suppressing Th17 cells [24]. How-
ever, recent studies of the frequency of Th17 cells in RA
patients have yielded conflicting data. Furthermore, the
profile of cytokines produced by these cells ex vivo and
their relationship with disease activity has not been well
defined. Some studies have only examined this popula-
tion in the blood of RA patients [25], whilst only two stu-
dies have examined these cells in SF or synovium [26,28].
We found no significant difference in the frequency of
IL-17-producing CD4 T cells in the blood of RA
patients and healthy controls. This contrasts with data
from the study of Shen et al. (which looked at blood
from 12 RA patients) but is consistent with data from
Yamada et al. (which looked at blood from 123 RA
patients and mononuclear cells isolated from the joints
of 12 patients) [25,28]. The study by Shen et al.,w h i l s t
primarily focussed on Th17 cells in ankylosing spondyli-
tis, demonstrated an increased frequency of IL-17-pro-
ducing CD4 T cells in RA patients blood compared to
healthy controls which correlated with both CRP and
swollen joint counts (SJC). We would suggest that the
larger sample sizes in our study (blood examined from
Church et al. Arthritis Research & Therapy 2010, 12:R184
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Page 7 of 13Figure 3 Analysis of IL-22 and IL-23R expression on IL-17-positive CD4 T cells in PBMC and SFMC of patients with RA. A) Representative
plots of the expression of IL-22 against IL-17 in CD4 T cells from isolated PBMC and SFMC are shown. B) The percentages of IL-17-positive CD4 T
cells coexpressing IL-22 in PBMC from healthy donors (n = 13), paired RA PBMC and SFMC samples (n = 14) are shown. C) The frequencies of IL-
22-positive CD4 T cells in HC PBMC, RA PBMC and paired SFMC are shown. D) Representative plots of the expression of IL-23R against IL-17 in
CD4 T cells from isolated PBMC and SFMC are shown. E) The percentages of IL-17-positive CD4 T cells coexpressing IL-23R in PBMC from healthy
donors (n = 13) and paired RA PBMC and SFMC samples (n = 11) are shown. F) The frequency of IL-23R-positive CD4 T cells was compared
between healthy donor PBMC (n = 13), RA PBMC and RA SFMC (n = 11). Bars representing the median are shown within the dot plots.
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provide a broader representation of what is recognised
to be a very heterogeneous disease.
Our observation of a small but significant increase in
the frequency of IL-17-producing CD4 T cells in SF
compared to peripheral blood of RA patients, and the
same for the frequency of memory CD4 T cells
(CD45RO-positive) producing IL-17, are consistent with
data from Shahrara et al. [26] but differ from the find-
ings of Yamada et al. [28]. It should be noted however
Figure 4 Coexpression of TNFa by IL-17-producing CD4 T cells in PBMC and SFMC of patients with RA. A) Representative plots of the
expression of TNFa against IL-17 in CD4 T cells from isolated PBMC and SFMC are shown. B) The percentages TNFa-positive CD4 T cells in
PBMC (n = 11) and SFMC (n = 11) of RA patients. C) The percentages of IL-17-positive CD4 T cells coexpressing TNFa in PBMC from healthy
donors (n = 11), paired RA PBMC and SFMC samples (n = 11) are shown. D) The frequencies of TNFa-positive IL-17-negative, TNFa-positive IL-
17-positive, TNFa-negative IL-17-positive gated on CD4 T cells in RA PBMC and SFMC are shown. Bars representing the median are shown
within the dot plot. The results of statistical analysis are shown within the plots. P-values less than 0.05 were considered significant.
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12 RA patients and data from synovial fluid (n =8 )a n d
synovial tissue (n = 4) were grouped together for analy-
sis; this may be relevant in the context of our observa-
tion that the percentage of Th17 cells was lower in
synovial tissue than in the blood of RA patients whereas
the reverse was seen when synovial fluid was compared
with blood.
Our data also demonstrate that there is marked varia-
bility in the frequency of IL-17-positive CD4 T cells in
SF between RA patients. The underlying cause for this
remains unclear but drug therapy may be a contributing
factor. As discussed, Yamada et al. reported that
patients taking prednisolone or MTX had a higher fre-
quency of IL-17-producing CD4 T cells, but could not
attribute this directly to treatment [28]. In our study we
did not observe this phenomenon. Most patients in this
study were receiving treatment with a non-steroidal
anti-inflammatory drug, a disease modifying anti-rheu-
matic drug, a biologic agent or a combination of these
(Table 1). We assessed the relationships between ther-
apy and frequencies of IL-17-positive CD4 T cells but
found no significant relationships. As it is not yet
known how current therapeutic regimes affect the fre-
quency of IL-17-producing CD4 T cells, it is possible
that medication, in addition to other factors, such as
disease duration and seropositivity, may contribute to
the heterogeneity in frequency of IL-17-producing CD4
T cells amongst patients studied here. In the context of
medication, appropriately designed longitudinal studies
would be needed to address the impact of drug therapy
on IL-17 producing cell populations.
IL-17-producing T cells were originally misclassified
under the Th1 umbrella. Since the characterisation of
Th17 cells, it has been identified that some IL-17-pro-
ducing T cells coexpress IFNg.T h i sI F N g-positive IL-
17-positive subset is particularly enriched in the gut of
patients with Crohn’s disease [36]. Here we found that
the majority of IL-17-producing CD4 T cells in the
blood and SF of patients with RA also coexpress IFNg.
However, in the SF we observe a greater frequency of
IFNg-positive IL-17-negative CD4 T cells compared
with blood, suggesting that Th1 cells and not Th17
cells predominate in the established RA joint. The rela-
tive paucity of IL-17-positive CD4 T cells in either the
SF or synovium is at odds with the high levels of IL-17
detected in RA SF [17-21]. One explanation may lie
with the use of a non-physiological stimulus in vitro,
such as PMA/ionomycin; stimuli in the RA joint, such
as antigen or cytokines, may drive a different cytokine
response in vivo. Ziolkowska et al. demonstrated that
RA PBMC produced significantly more IL-17 than
SFMC when challenged with PMA/ionomycin in vitro,
however, stimulation with IL-15 induced greater IL-17
production from SFMC than PBMC [21]. It is thus
possible that the inflammatory environment of the
rheumatoid synovium drives Th17 cells to produce IL-
17 in a cytokine-dependent manner. In addition, the
c o n c e p tt h a tC D 4Tc e l l sm a yn o tb et h eo n l ys o u r c e
of IL-17 in the joint is being increasingly recognised.
Mast cells have recently been identified as a source of
IL-17 in RA synovium and are potent producers of IL-
17 upon stimulation with TNFa, immune complexes
and LPS [37].
IL-22 has been characterised as one of the effector
cytokines secreted by Th17 cells [9,30,31], but it is also
produced by Th1 cells [38]. Although this novel cyto-
kine belongs to the IL-10 family, it is proinflammatory
in function [39]. In animal models such as CIA, IL-22 is
proinflammatory, whilst IL-22(-/-) mice are less suscep-
tible to CIA than wild-type mice [32]. In human studies,
IL-22 has been proposed to play a role in the pathogen-
esis of autoimmune inflammatory diseases, such as
psoriasis [40] and Crohn’s disease [41,42]. In RA,
expression of IL-22 was found to be upregulated in
synovium and capable of inducing synovial fibroblast
proliferation and chemokine production [33]. Here, we
found that IL-17-producing CD4 T cells in the SF coex-
pressed very little IL-22. Furthermore, we identified an
IL-22-producing CD4 T cell population distinct from
IL-17-producing CD4 T cells, but this population was
n o te l e v a t e di nt h eb l o o do fR Ap a t i e n t sc o m p a r e dt o
healthy controls nor was it enriched in RA SF. This
CD4 T cell subset may be similar to that recently
reported to secrete IL-22 but not IL-17 and to be
involved in the skin pathophysiology of psoriasis
[43,44]. The paucity of IL-22-producing CD4 T cells in
SF lends support to the notion that the primary source
of IL-22 in the joint is not T cells but rather synovial
fibroblasts and/or macrophages as reported by Ikeuchi
et al. [33].
IL-22 production by Th17 cells has been shown to be
dependent upon IL-23 [38,45,46], thus our observation,
which corroborates that of Shen et al. [25], that very
few IL-17-producing CD4 T cells express IL-23R
provides a potential explanation for the paucity of IL-
22-positive IL-17-positive CD4 T cells we observed.
Considering the importance of IL-23 to the development
and maintenance of Th17 cells, it is striking that over
90% and 85% of IL-17-producing CD4 T cells in the SF
and blood respectively did not express IL-23R. However,
our data are consistent with recent evidence showing
that bioactive IL-23 (p19/p40) was barely detectable in
joints of patients with RA [47].
In contrast to the pattern of IL-22 expression, the
majority of IL-17-producing CD4 T cells in SF coex-
pressed TNFa; these double positive cells were signifi-
cantly elevated in SF compared to blood. Although the
Church et al. Arthritis Research & Therapy 2010, 12:R184
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sing TNFa i sv e r ys m a l lc o m p a r e dt ot h a to fT N F a-
producing CD4 T cells found in the SF, this may be
relevant in terms of therapy. One of the mechanisms
by which monoclonal antibodies against TNFa mediate
their therapeutic effects, in addition to TNFa blockade,
may be through induction of apoptosis in monocytes
and T cells by outside to inside signalling through
transmembrane TNFa [48-50]. Membrane expression
of TNFa on IL-17-producing CD4 T cells would make
these cells a potential target of monoclonal antibodies
and may help to explain the beneficial effects of these
therapies.
Upon identification of the IL-17/IL-23 axis, Th17 cells
were viewed as a driving force in the pathogenesis of
several autoimmune diseases previously associated with
a Th1 predominance. In the case of multiple sclerosis
evidence has supported this shift in paradigm [51,52].
However in RA, evidence is less clear. There is no
doubt that cytokines associated with the Th17 lineage,
such as IL-17, IL-6, IL-1b, IL-22, can be found within
the RA joint [20,33], and as demonstrated here, there is
evidence for a small but significant enrichment of Th17
cells within RA SF. In our study, however, we have only
examined established RA and many patients had long-
standing severe disease; thus 60% (6 of 10) of patients
from whom synovial tissue was obtained and 29% (4 of
14) from whom synovial fluid was obtained were on
anti-TNF agents. Recent data from Colin et al. and pre-
vious data from our group suggest that the situation
may be different in the early phase of RA [15,20].
Further studies are required to define the role of Th17
cells in the early phase of disease. The absence of an
enrichment of Th17 cells in the synovial tissue of estab-
lished RA patients is paradoxical to the role this cyto-
kine is reported to play in the pathogenesis of RA
[17-21]. This leaves the possibilities that Th17 cells
located outside the synovium, such as the juxta-articular
bone marrow, may be an additional source of IL-17,
that other cells in the synovium, including mast cells
[37] may also produce IL-17 or that the experimental
techniques used to reveal IL-17 production ex vivo do
not reveal the true potential of T cells in the rheuma-
toid joint to produce IL-17. Future work will need to
address these issues.
Conclusions
Our findings demonstrate a modest enrichment of IL-
17-producing CD4 T cells in RA synovial fluid com-
pared to peripheral blood. Th17 cells in synovial fluid
produce more TNF than their peripheral blood counter-
p a r t s ,b u ta r en o tas i g n i f i c a n ts o u r c eo fI L - 2 2a n dd o
not express IL-23R. However, the percentage of CD4 T
cells which produce IL-17 in the rheumatoid joint is
low, suggesting that other cells may be alternative
sources of IL-17 within the joints of RA patients.
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